Boston Scientific Reports Third Quarter 2026 Results
Boston Scientific Corporation (NYSE: BSX) has announced its financial results for the third quarter of 2026. The company reported net sales of $5.138 billion, representing a 1.5% increase on a reported, operational, and organic basis compared to the prior year period.
The company's GAAP net income attributable to Boston Scientific common stockholders was $582 million, or $0.40 per share, compared to $755 million, or $0.51 per share, in the same period last year. Adjusted earnings per share (EPS) for the quarter was $0.73, down from $0.75 in the prior year period.
Boston Scientific's chairman and CEO, Mike Mahoney, expressed pride in the company's response to the recent cybersecurity incident, stating, "I'm proud of how our global teams have responded, particularly to the cybersecurity incident, working with urgency and resilience to restore operations and continue supporting customers and patients."
The company has provided guidance for the full year and fourth quarter of 2026, estimating net sales growth of approximately 4.25% on a reported basis and 3.75% on an organic basis for the full year. Adjusted EPS is expected to be between $3.16 and $3.18 for the full year. For the fourth quarter, net sales are expected to decline by approximately (3.0)% to (1.0)% on a reported and organic basis, with adjusted EPS expected to be between $0.77 and $0.79.
